SCHEMBL25544331

SCHEMBL25544331

Cc1ccc2c(Cl)c(C(C)C)c(C)nc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
ACHE P22303 4/20 0.38
BCHE P06276 3/20 0.37
GRIN1 Q05586 3/20 0.37
GRIN2A Q12879 3/20 0.37
PKM P14618 1/20 0.37
GRM2 Q14416 2/20 0.36
ALB P02768 2/20 0.36
LDHA P00338 1/20 0.36
LDHB P07195 1/20 0.36
HRH4 Q9H3N8 1/20 0.35
DHODH Q02127 1/20 0.35
NQO2 P16083 1/20 0.35
CYP1A2 P05177 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30120959 0.84 TRPV1 (0.37) ALDH1A1KDM4EMAPTKMT2A
SCHEMBL23887701 0.84 TRPV1 (0.37) ALDH1A1KDM4EMAPTKMT2A
SCHEMBL23887808 0.81 MPO (0.47) ALDH1A1LMNAKDM4EMAPTACHE
SCHEMBL25544333 0.80 ALB (0.45) ALDH1A1LMNAKDM4EMAPTACHE
SCHEMBL7125134 0.79 MAOA (0.53) ALDH1A1KDM4EMAPTDHODHCYP1A2
SCHEMBL11985935 0.79 ALDH1A1 (0.42) ALDH1A1LMNAKDM4EMAPTACHE
SCHEMBL9595057 0.78 NQO2 (0.50) ALDH1A1LMNAKDM4EMAPTACHE
SCHEMBL30367341 0.76 MPO (0.34) ALDH1A1LMNAKDM4EMAPTKMT2A
SCHEMBL28974954 0.76 MPO (0.34) ALDH1A1LMNAKDM4EMAPTKMT2A
SCHEMBL9595142 0.72 LMNA (0.55) ALDH1A1LMNAKDM4EMAPTACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 ALDH1A1 542/4885LMNA 1470/4885KDM4E 4440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.